GlassScriptPhysician profile
Tessa E Wigger
NPI 1497919344
$8,163.01
in general payments reported to CMS, 2019-2025
43 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.14 · 2020: $587 · 2021: $1,203 · 2022: $1,371 · 2023: $1,615 · 2024: $2,017 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,214.09 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $997.93 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $821.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $597.04 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $580.48 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $454.12 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $437.97 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.58 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $411.97 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $217.43 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $182.61 | 2023-2025 | |
| Eisai INC. | $181.97 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $145.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $144.38 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $117.35 | 2021-2023 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $113.27 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $99.19 | 2020-2025 | Capvaxive, Gardasil 9 |
| Allergan, INC. | $76.98 | 2020 | |
| Hologic Sales and Service, LLC | $76.19 | 2023-2024 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.55 | 2021-2025 | Jardiance |
| Dexcom, INC. | $72.32 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $68.22 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.68 | 2021-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $60.72 | 2023-2024 | Quviviq |
| Daiichi Sankyo INC. | $53.14 | 2021 | |
| Neurocrine Biosciences, INC. | $50.60 | 2022-2023 | Ingrezza |
| Currax Pharmaceuticals LLC | $47.02 | 2024-2025 | Contrave |
| Janssen Pharmaceuticals, INC | $44.53 | 2021 | |
| Corcept Therapeutics | $39.48 | 2024 | Korlym |
| Ibsa Pharma INC. | $34.54 | 2021 | |
| Scilex Pharmaceuticals INC. | $24.37 | 2023 | Ztlido |
| Medtronic, INC. | $23.90 | 2024 | Intellis Adaptivestim |
| Neuronetics, INC. | $23.89 | 2025 | Neurostar Tms Therapy System |
| Sanofi Pasteur INC. | $23.65 | 2023 | |
| Shield Therapeutics INC | $21.61 | 2024 | |
| Amarin Pharma, INC. | $20.38 | 2020 | |
| Genentech USA, INC. | $18.16 | 2020 | |
| Boston Scientific Corporation | $16.70 | 2023 | Watchman Flx |
| Si-Bone, INC. | $16.59 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.27 | 2024 | Voquezna |
| Radiometer America, INC | $14.79 | 2021 | |
| Philips North America LLC | $14.46 | 2024 | (Ck7) Extended Holter |
| Kowa Pharmaceuticals America, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tessa Wigger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.